Peginterferon beta-1a

{{Short description|Medication}}

{{Use American English|date=August 2023}}

{{Use dmy dates|date=August 2023}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| image =

| width =

| alt =

| image2 =

| width2 =

| alt2 =

| caption =

| pronounce =

| tradename = Plegridy, Plegridy Pen

| Drugs.com = {{drugs.com|monograph|peginterferon-beta-1a}}

| MedlinePlus = a614059

| DailyMedID = Peginterferon beta-1a

| pregnancy_AU = D

| pregnancy_AU_comment = {{cite web | title=Peginterferon beta-1a (Plegridy) Use During Pregnancy | website=Drugs.com | date=22 July 2019 | url=https://www.drugs.com/pregnancy/peginterferon-beta-1a.html | access-date=25 June 2020}}

| pregnancy_category=

| routes_of_administration = Subcutaneous injection

| class = Antineoplastic agent

| ATC_prefix = L03

| ATC_suffix = AB13

| ATC_supplemental =

| legal_AU = S4

| legal_AU_comment = {{cite web | title=Prescription medicines: registration of new chemical entities in Australia, 2014 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/resources/resource/guidance/prescription-medicines-registration-new-chemical-entities-australia-2014 | access-date=10 April 2023}}

| legal_BR =

| legal_BR_comment =

| legal_CA = Rx-only

| legal_CA_comment = {{cite web | title=Health Canada New Drug Authorizations: 2015 Highlights | website=Health Canada | date=4 May 2016 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2015-highlights.html | access-date=7 April 2024}}

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment =

| legal_EU = Rx-only

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status = Rx-only

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 1211327-92-2

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank = DB09122

| ChemSpiderID =

| UNII = I8309403R0

| KEGG = D10483

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = BIIB-017

| IUPAC_name = 1-Ether with N-(3-hydroxy-2-methylpropyl)interferon β-1a (human) α-methyl-ω-hydroxy-poly(oxy-1,2-ethanediyl)

| chemical_formula = C913H1417N246O256PS7 [C2H4O]n

| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I=

| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=

| molecular_weight = 44000

| molecular_weight_comment = g·mol⁻¹

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.

The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.{{cite web | title=Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution | website=DailyMed | date=30 March 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08f0ea03-4e6d-195d-aef4-886e32befa95 | access-date=25 June 2020}}

Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.{{cite web | title=Drug Approval Package: Plegridy (peginterferon beta-1a) prefilled syringe and Plegridy Pen (peginterferon beta-1a) prefilled pen NDA #125499 | website=U.S. Food and Drug Administration (FDA) | date=17 September 2014 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125499Orig1s000TOC.cfm | archive-url=https://web.archive.org/web/20200626040923/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125499Orig1s000TOC.cfm | url-status=dead | archive-date=26 June 2020 | access-date=25 June 2020}}{{cite web | title=Plegridy EPAR | website=European Medicines Agency (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy | access-date=24 June 2020}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.